The availability, diversion and injection of pharmaceutical opioids in South Asia

Drug and Alcohol Review

Volumn 30, Issue 3, 2011, Pages 246-254

  Larance, Briony ^a   Ambekar, Atul ^b   Azim, Tasnim ^c   Murthy, Pratima ^d   Panda, Samiran ^e   Degenhardt, Louisa ^f   Mathers, Bradley ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^d NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^e INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^f BURNET INSTITUTE   (Australia)

Author keywords

Diversion; Injection; Misuse; Pharmaceutical opioid; South Asia

Indexed keywords

NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG;

ASIA; DRUG INDUSTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OPIATE ADDICTION; PAIN; REVIEW; STANDARD; SUBSTANCE ABUSE;

ANALGESICS, OPIOID; ASIA; DRUG INDUSTRY; HIV INFECTIONS; HUMANS; OPIOID-RELATED DISORDERS; PAIN; PRESCRIPTION DRUGS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 79955575426     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/j.1465-3362.2011.00304.x     Document Type: Review

References (97)

1. [1] World Health Organisation. WHO Model List of Essential Medicines: 15th Edition (March 2007). Essential Medicines Library 2007. Available at: (accessed June 2009).
2. [2] Kumar S. Injecting of pharmaceutical drugs in the SAARC region: a review. Chennai; 2006.
3. [3] Kumar S. Medical consequences of injecting pharmaceutical drugs: HIV/AIDS. Injecting pharmaceuticals and the HIV epidemic in South Asia December 11-13th, 2006. New Delhi, India 2006.
4. [4] Rajagopal MR, Joranson DE. India: opioid availability-an update. J Pain Symptom Manage 2007;33:615-22.
5. [5] Rajagopal MR, Joranson DE, Gilson AM. Medical use, misuse, and diversion of opioids in India. Lancet 2001;358:139-43.
6. [6] Sharma M, Oppenheimer E, Saidel T, Loo V, Garg R. A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region. AIDS 2009;23:1405-13.
7. [7] Tandon T. Policy environment for drug control in South Asia: findings from a legal and political review of IDU harm reduction in SAARC. Injecting pharmaceuticals and the HIV epidemic in South Asia December 11-13th, 2006. New Delhi, India 2006.
8. [8] UNHCR. Behavioural Surveillance Survey among Refugees and Surrounding Host Community: Jhapa and Morang districts. Nepal: HIV/AIDS Unit, UNHCR, 2005.
9. [9] United Nations Office on Drugs and Crime. South Asia 2005-2007: strategic programme framework. Vienna: United Nations Office on Drugs and Crime, 2007.
10. [10] United Nations Office on Drugs and Crime Regional Office for South Asia. South Asia Regional Profile: Drugs and Crime: United Nations Office on Drugs and Crime. 2005.
11. [11] United Nations Office on Drugs and Crime Regional Office for South Asia. South Asia 2005-2007: Strategic Programme Framework: United Nations Office on Drugs and Crime. 2007.
12. [12] UNODC Regional Office for South Asia. Rapid Situation and Response Assessment of Drugs and HIV in Bangladesh, Bhutan, India, Nepal and Sri Lanka: A Regional Report: United Nations Office of Drugs and Crime, Regional Office for South Asia (UNODC ROSA). 2008.
13. [13] Mathers B, Degenhardt L, Phillips B, etal. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008;372:1733-45.
14. [14] Altaf A, Saleem N, Abbas S, Muzaffar R. High prevalence of HIV infection among injection drug users (IDUs) in Hyderabad and Sukkur, Pakistan. J Pak Med Assoc 2009;59:136-40.
15. [15] Ambekar A, Vaswani M. Drug abuse-related HIV/AIDS epidemic in India: situation and responses. In: Browne-Miller A, ed. The Praeger International Collection on Addictions. Westport, CT: Praeger Publishers, 2009:235-60.
16. [16] Azim T, Khan SI, Nahar Q, etal. 20years of HIV in Bangladesh: experiences and way forward: The World Bank and UNAIDS. 2009.
17. [17] Azim T, Rahman M, Alam MS, etal. Bangladesh moves from being a low-prevalence nation for HIV to one with a concentrated epidemic in injecting drug users. Int J STD AIDS 2008;19:327-31.
18. [18] Bergenstrom A, Chowdhury EI, Reza M, Alam MS, Hoque M, Azim T. Bangladesh Country Advocacy Brief: Injecting Drug Use and HIV. Bangkok: United Nations Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific, 2009.
19. [19] Platt L, Vickerman P, Collumbien M, etal. Prevalence of HIV, HCV and sexually transmitted infections among injecting drug users in Rawalpindi and Abbottabad, Pakistan: evidence for an emerging injection-related HIV epidemic. Sex Transm Infect 2009;85:ii17-22.
20. [20] Sarkar K, Bal B, Mukherjee R, etal. Epidemic of HIV coupled with hepatitis C virus among injecting drug users of Himalayan West Bengal, Eastern India, Bordering Nepal, Bhutan, and Bangladesh. Subst Use Misuse 2006;41:341-52.
21. [21] Soloman SS, Srikrishnan AK, Mehta SH, etal. High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviours among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr 2008;49:327-32.
22. [22] Todd CS, Abed A, Strathdee SA, etal. HIV, hepatitis C and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan. Emerg Infect Dis 2007;13:1327-31.
23. [23] United Nations (ed.). Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol amending the Single Convention on Narcotic Drugs, 1961. 1972. Available at: (accessed June 2009).
24. [24] International Narcotics Control Board. Narcotic Drugs: Estimated World Requirements for 2006. Vienna: United Nations, 2006.
25. [25] International Narcotics Control Board. Annual Report of the INCB 2006. Vienna: United Nations, 2007.
26. [26] Degenhardt L, Larance B, Mathers B, etal. Benefits and risks of pharmaceutical opioids: essential treatment and diverted medication. A global review of availability, extra-medical use, injection and the association with HIV. Thematic paper undertaken by the Reference Group to the United Nations on HIV and injecting drug use Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2008.
27. [27] Pain and Policy Studies Group. Availability of opioid analgesics in Eastern Europe. Madison: University of Wisconsin Pain & Policy Studies Group/WHO Collaborating Center for Policy and Communications in Cancer Care, 2002.
28. [28] International Narcotics Control Board. Narcotic drugs: estimated world requirements 2007. Vienna: United Nations, 2008.
29. [29] International Narcotics Control Board. Psychotropic substances: 2005 assessments of annual medical and scientific requirements. Vienna: United Nations, 2006.
30. [30] United Nations Office on Drugs and Crime Regional Office for South Asia. South Asia 2005-2007: Strategic Programme Framework: United Nations Office on Drugs and Crime. 2005.
31. [31] Paoli L, Greenfield VA, Charles M, Reuter P. The global diversion of pharmaceutical drugs. India: the third largest illicit opium producer? Addiction 2009;104:347-54.
32. [32] Ministry of Commerce and Industry. Strategy for increasing exports of pharmaceutical products: report of the task force: Department of Commerce, Government of India. 2008.
33. [33] Indian Express. 72, 000 Norphine injections seized. Indian Express 2003.
34. [34] Emmanuel F, Fatima M. Coverage to curb the emerging HIV epidemic among injecting drug users ion Pakistan: delivering prevention services where most needed. Int J Drug Policy 2008;19(Suppl. 1):S59-64.
35. [35] Panda S, Sharma M. Needle syringe acquisition and HIV prevention among injecting drug users: a treatise on the 'Good' and 'Not So Good' public health practices in South Asia. Subst Use Misuse 2006;39:9.
36. [36] WHO Expert Committee on Drug Dependence. Thirty-third report. WHO Technical Report Series 915. Geneva: WHO, 2003.
37. [37] Ahmed SK, Ara N. An exploratory study of buprenorphine use in Bangladesh: a note. Subst Use Misuse 2001;36:1071-83.
38. [38] Jenkins C, Rahman H, Saidel T, Jana S, Hussain AM. Measuring the impact of needle exchange programs among injecting drug users through the National Behavioural Surveillance in Bangladesh. AIDS Educ Prev 2001;13:452-61.
39. [39] Azim T, Chowdhury EI, Reza M, etal. Prevalence of infections, HIV risk behaviours and factors associated weith HIV infection among male injecting drugs users attending a Needle /Syringe Program in Dhaka, Bangladesh. Subst Use Misuse 2009;43:2124-44.
40. [40] Gupta S. Narco Hiccough. 2010. Available at: (accessed February 2010).
41. [41] Panda S, Chatterjee A, Sarkar S, etal. Injection drug use in Calcutta: a potential focus for an explosive HIV epidemic. AIDS Educ Prev 1997;16:17-23.
42. [42] UNODCCP, UNAIDS. Baseline study of the relationship between injecting drug use, HIV and hepatitis C among male injecting drug users in Lahore. Lahore: UNODCCP/UNAIDS, 1999.
43. [43] Reid G, Costigan G. Revisiting 'The Hidden Epidemic': a situation assessment of drug use in Asia in the context of HIV/AIDS. Melbourne: Burnet Institute Centre for Harm Reduction, 2002.
44. [44] Kermode M, Longleng V, Singh BC, Hocking J, Langkham B, Crofts N. My first time: initiation into injecting drug use in Manipur and Nagaland, north-east India. Harm Reduct J 2007;4:1-11.
45. [45] Basu D, Mattoo SK, Malhotra A, Gupta N, Malhotra R. A longitudinal study of male buprenorphine addicts attending an addiction clinic in India. Addiction 2000;95:1363-72.
46. [46] Republic of Maldives Narcotics Control Board. Rapid situation assessment of drug abuse in Maldives, 2003. Mali: Narcotics Control Board, 2003.
47. [47] World Bank. HIV/AIDS in Afghanistan. November 2006; 2006.
48. [48] Ayed FB, Rais H, Gharbi N, etal. Opioid dispensation by pharmacists in Tunisia. [French]. Therapie 2001;56:711-17.
49. [49] Koehler U. Critical contributing factors of pharmaceutical injecting in Afghanistan. Injecting pharmaceuticals and the HIV epidemic in South Asia December 11-13th, 2006. New Delhi, India 2006.
50. [50] Zafar T, Brahmbhatt H, Imam G, Ul Hassan S, Strathdee SA. HIV knowledge and risk behaviors among Pakistani and Afghani drug users in Quetta, Pakistan. J Acquir Immune Defic Syndr 2003;32:394-8.
51. [51] Azim T. Vulnerability to HIV infection among sex worker and non-sex worker female injecting drug users in Dhaka, Bangladesh: evidence from the baseline survey of a cohort study. Harm Reduct J 2006;3:33.
52. [52] Azim T, Rahman M, Alam S, Rahman M, Reza M, Chowdhury IA. National HIV Serological Surveillance 2006, Bangladesh: 7th Technical Report. Dhaka: National AIDS/STD Programme (NASP), Directorate General of Health Services, Ministry of Health and Family Welfare (MOHFW), 2007.
53. [53] Azim T, Khan SI, Haseen F, etal. HIV and AIDS in Bangladesh. J Health Popul Nutr 2008;26:311-24.
54. [54] United Nations Office on Drugs and Crime, Regional Office for South Asia, Ministry of Social Justice and Empowerment. Injecting drug use and HIV in India: an emerging concern. New Delhi; 2004.
55. [55] Ambekar A, Tripathi BM. Size estimation of injecting drug use in Punjab and Haryana. New Delhi: United Nations Programme on HIV/AIDS and Society for Promotion of Youth and Masses, 2008.
56. [56] Ambekar A, Dhawan A. Buprenorphine maintenance: the experience of NDDTC. Injecting pharmaceuticals and the HIV epidemic in South Asia December 11-13th, 2006. New Delhi, India 2006.
57. [57] Grover S, Irpati AS, Saluja BS, Mattoo SK, Basu D. Substance-dependent women attending a de-addiction center in North India: sociodemographic and clinical profile. Indian J Med Sci 2005;59:283-91.
58. [58] Chowdhury AN, Chowdhury S. Buprenorphine abuse: report from India. Br J Addict 1990;1990:1349-50.
59. [59] Lal Kapoor S. A study of women substance users and sex trade workers in India. UNDCP-ROSA study. Mumbai: Mukti Sadan Foundation, 2006.
60. [60] Mahanta J, Medhi GK, Paranjape RS, etal. Injecting and sexual risk behaviours, sexually transmitted infections and HIV prevalence in injecting drug users in three states in India. AIDS 2008;22(Suppl. 5):S59-68.
61. [61] Ambekar A, Tripathi BM. Knowledge, attitude, behaviour and practices of drug users in India. New Delhi: Society for Promotion of Youth & Masses (SPYM) in partnership with National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, supported by Department for International Development, UK. 2006.
62. [62] Murthy P. Women and Drug Abuse in India. Substance, Women and High Risk Assessment Study: United Nations Office on Drugs and Crime, Ministry of Social Justice and Empowerment, Government of India, UNIFEM. 2008.
63. [63] Ambekar A, Tripathi BM, Dzuvichu B. HIV Vulnerability among IDUs, their Spouses and Children: Society for Promotion of Youth and Masses, New Delhi and Plan International, India. 2009.
64. [64] National AIDS Control Organization. National Behavioural Surveillance Survey 2006: Men who have Sex with Men (MSM) and Injecting Drug Users (IDUs): Ministry of Health and Family Welfare, Government of India. 2007.
65. [65] Department of AIDS Control. Annual Report 2008-2009. India: Ministry of Health and Family Welfare, Government of India, 2009.
66. [66] Chatterjee A, Uprety L, CHapagain M, Kafle K. Drug abuse in Nepal: a rapid assessment study. Bull Narc 1996;48:11-33.
67. [67] Pathak LR, Tavitian-Exley I, Acharya LB, Arscott-Mills S, Maw-Naing A. HIV surveillance as a dynamic component of strategic information in an evolving epidemic. Conference paper presented at Second Global Surveillance meeting. Bangkok, Thailand 2009.
68. [68] Shahzad F. Regulation of narcotic psychotropic and other controlled subtances in Pakistan. In: Personal communication to: Secretariat of the Reference Group to the United Nations on HIV and IDU, ed. 2007.
69. [69] de Kort G, Batra S, Pasaribu R, Vazirian M, Ul-Hassan S. Young people and drugs: towards a comprehensive health promotion policy. Chiang Mai: Asian Harm Reduction Network, 2005.
70. [70] Ahmed MA, Zafar T, Brahmbhatt H, etal. HIV/AIDS risk behaviors and correlates of injection drug use among drug users in Pakistan. J Urban Health 2003;80:321-9.
71. [71] Parviz S, Fatmi Z, Altaf A, etal. Background demographics and risk behaviors of injecting drug users in Karachi, Pakistan. Int J Infect Dis 2006;10:364-71.
72. [72] Strathdee SA, Zafar T, Brahmbhatt H, Baksh A, ul Hassan S. Rise in needle sharing among injection drug users in Pakistan during the Afghanistan war. Drug Alcohol Depend 2003;71:17-24.
73. [73] Zindagi N. Critical contributing factors of pharmaceutical injecting in Pakistan. Injecting pharmaceuticals and the HIV epidemic in South Asia December 11-13th, 2006. New Delhi, India 2006.
74. [74] World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO Press, 2009.
75. [75] Clarke S, Keenan E, Ryan M, Barry M, Mulcahy F. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Read NY 2002;12:305-16.
76. [76] Macalino GE, Mitty J, Bazerman L, Singh K, McKenzie M, Flanigan T. Modified directly observed therapy for the treatment of HIV-seropositive substance users: lessons learned from a pilot study. Clin Infect Dis 2004;38:S393-7.
77. [77] Wolfe D. Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union. Int J Drug Policy 2007;18:246-54.
78. [78] World Health Organization/United Nations Office on Drugs and Crime/Joint United Nations Programme on HIV/AIDS. Substitution maintenance therapy in the management of opioid dependence and HIV/aids prevention. Geneva: World Health Organization, 2004.
79. [79] Gowing L, Farrell M, Bornemann R, Sullivan LE, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2008;(2):Art. No.: CD004145. DOI:10.1002/14651858.CD004145.pub3.
80. [80] Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010;376:285-301.
81. [81] De S, Jain R, Ray R, Dhawan A, Varghese S. Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects. Indian J Physiol Pharm 2008;52:53-63.
82. [82] Thirthalli J, Chand PK. The implications of medication development in the treatment of substance use disorders in developing countries. Curr Opin Psychiatry 2009;22:274-80.
83. [83] Kumar MS, Natale RD, Langkham B, Sharma C, Kabi R, Mortimore G. Opioid substitution treatment with sublingual buprenorphine in Manipur and Nagaland in Northeast India: what has been established and needs to be continued and expanded. Harm Reduct J 2009;6:1-5.
84. [84] Dhawan A, Sunder S. Opioid substitution therapy: the Indian experience. In: Ambekar A, Tripathi BM, eds. Drug abuse: News-n-views (harm reduction: prevention of HIV among drug users). New Delhi: National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, 2008:4-5.
85. [85] Mathers B, Degenhardt L, Ali H, etal. HIV prevention, treatment and care services for people who inject drugs: a systematic review of global, regional and national coverage. Lancet 2010;375:1014-28.
86. [86] Todd CS, Abed AMS, Scott P, Safi N, Earhart K, Strathdee SA. A cross-sectional assessment of utilisation of addiction treatment among injecting drug users in Kabul, Afghanistan. Subst Use Misuse 2009;44:416-30.
87. [87] Achakzai M, Kassi M, Kasi PM. Seroprevalences and co-infections of HIV, hepatitis C virus and hepatitis B virus in injecting drug users in Quetta, Pakistan. Trop Doct 2007;37:43-5.
88. [88] Khan AA, Awan AB, Queshi SU, Razaque A, Zafar ST. Large sharing networks and unusual injection practices explain the rapid rise in HIV among IDUs in Sargodha, Pakistan. Harm Reduct J 2009;6:13.
89. [89] Emmanuel F, Archibald C, Razaque A, Sandstrom P. Factors associated with an explosive HIV epidemic among injecting drug users in Sargodha, Pakistan. J Acquir Immune Defic Syndr 2009;51:85-90.
90. [90] Sharma D. Poor palliative care in India. Lancet Oncol 2008;9:515.
91. [91] World Health Organisation. Lexicon of alcohol and drug terms. 2007. Available at: (accessed July 2007).
92. [92] Simoni-Wastila L, Tompkins C. Balancing diversion control and medical necessity: the case of prescription drugs with abuse potential. Subst Use Misuse 2001;36:1275-96.
93. [93] Resource Centre for Sexual Health and AIDS (RCSHA). Report of the Expert Group on Size Estimation of Population with High Risk Behaviour for NACP-III Planning. New Delhi: RCSHA, 2006.
94. [94] Reddy A, Hoque MM, Kelly R. HIV transmission in Bangladesh: an analysis of IDU programme coverage. Int J Drug Policy 2008;19(Suppl. 1):S37-46.
95. [95] Basak SC, Sathyanarayana D. Community pharmacy practice in India: past, present and future. South Med Rev 2009;2:11-14.
96. [96] Vorobjov S, Uusküla A, Abel-Ollo K, Talu A, Rüütel K, Des Jarlais DC. Comparison of injecting drug users who obtain syringes from pharmacies and syringe exchange programs in Tallinn, Estonia. Harm Reduct J 2009;6:1-8.
97. [97] Pankonin CA, Higgs P, Reid G, Aitken C. Selling syringes to injecting drug users: a study of five pharmacies in Hanoi, Vietnam. J Infect Dev Ctries 2008;2:51-8.